Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
indoleamine 2,3-dioxygenase inhibitor |
| gptkbp:CASNumber |
1204669-58-8
|
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:hasMolecularFormula |
C17H14ClN3O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
navoximod
|
| gptkbp:intendedUse |
immunotherapy
|
| gptkbp:mechanismOfAction |
IDO1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:GDC-0919
|
| gptkbp:bfsParent |
gptkb:IDO1
|
| gptkbp:bfsLayer |
7
|